Lack of Flexible Software Licensing Costing Vendors, Finds Thales
12.1.2022 11:00:00 EET | Business Wire | Press release
More than 90% of independent software vendors and intelligent device vendors (ISVs and IDVs) are missing out on revenue because they’re not offering the flexible licensing models customers demand, new research from Thales has revealed. Of those vendors, over half (54%) admit that this is due to their customers requiring more flexible license models.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220112005065/en/
©Thales
This research comes as the software delivery and entitlement management landscape is changing. Surveying more than 400 global ISVs and IDVs, the 2022 Thales State of Software Monetization Report has found that nearly three quarters (74%) of software vendors expect an increase in the delivery of software-as-a-service (SaaS) via the cloud, while two thirds (66%) anticipate increased delivery of software in a hybrid manner that leverages both on-premises and the cloud.
Vendors cited significant benefits gained from approaches like SaaS, with improved user experience (40%) deemed the most important, ahead of better customer value (34%) and increased revenue opportunities (30%). However, the push towards a digital approach also means considerable challenges for vendors when it comes to licensing and entitling their software. In fact, a full 40% of those surveyed admit to experiencing challenges in licensing their solutions across multiple devices, while the same number report struggling with different deployment environments. Over a third (37%) find it hard supporting the growing number of users who work remotely.
Compliance and misuse costing vendors
On top of these challenges, vendors could also lose out due to customer misuse and compromised software. ISVs and IDVs estimated that more than a quarter of their software was unlicensed in the last year.
Nearly all vendors surveyed (90%) say their revenue is directly impacted by licensing agreement violations and are worried that their software might be stolen, tampered with or copied.
It’s clear that vendors need to offer flexible licensing and entitlement management in order to meet customers’ varying needs,” said Jake Fox, Vice President, Software Monetization, Product Engineering & Services at Thales. “In order to take advantage of the increased demand for more choices in deployment, packaging and managing entitlements, vendors must invest in new technologies and ensure their businesses are prepared to offer software in a variety of ways. Those who lead the way with flexible entitlements will gain in market share, while those who do nothing risk being left behind in an increasingly competitive landscape.”
Data use key to improving revenue
In order to execute an effective software monetization and licensing strategy, software vendors will need to better understand how their software is being utilized by end-users. Doing so will drive forward smarter innovation and improvements in products. Fortunately, over half (54%) of vendors plan to take greater advantage of data for business intelligence. The data points that vendors are relying on, focus heavily on feature usage, and include the features users search for most (43%), , least popular features(41%) and the features used most and least often (41%).
Fox continued. “Data should be an essential part of any successful business, but it must be used properly. Data can lay the groundwork for future product development, ensuring the business is investing in the areas that customers are using. On top of that, it can also underpin software growth strategies by enabling businesses to tweak entitlements, agreements and packaging in real-time to suit customer needs, in turn securing maximum return on their investments.”
About Thales
Thales (Euronext Paris: HO) is a global leader in advanced technologies, investing in digital and “deep tech” innovations – connectivity, big data, artificial intelligence, cybersecurity and quantum computing – to build a confident future crucial for the development of our societies. The Group provides its customers – businesses, organisations and governments – in the defense, aeronautics, space, transport, and digital identity and security domains with solutions, services and products that help them fulfil their critical role, consideration for the individual being the driving force behind all decisions.
Thales has 81,000 employees in 68 countries. In 2020 the Group generated sales of €17 billion.
PLEASE VISIT
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220112005065/en/
Contact information
PRESS CONTACT
Thales, Media Relations Security
Vanessa Viala
+33 (0)4 42 36 58 63
vanessa.viala@thalesgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
